QUOC NGUYEN: Open Payments
NPI 1639121379 · TEMECULA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,088 in 26 payments from 14 companies in 2025. Trend: 2023 $889 · 2024 $686 · 2025 $1,088
Food & beverage: $1,023Education: $65
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $219 |
| ABBVIE INC. | 5 | $187 |
| Neurocrine BioSciences, Inc. | 1 | $140 |
| E.R. Squibb & Sons, L.L.C. | 1 | $135 |
| Grifols USA, LLC | 3 | $83 |
| HARMONY BIOSCIENCES LLC | 1 | $65 |
| GENZYME CORPORATION | 2 | $60 |
| Verona Pharma, Inc. | 2 | $53 |
| Janssen Pharmaceuticals, Inc | 1 | $42 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $33 |
Products named: VRAYLAR, INGREZZA, COBENFY, NUCALA, TRELEGY ELLIPTA, DUPIXENT, Prolastin-C Liquid, Ohtuvayre.
Industry payments across CA — which companies pay providers there.
